Correlation between benign prostatic hyperplasia and inflammation

Current Opinion in Urology

Volumn 23, Issue 1, 2013, Pages 5-10

  Bostanci, Yakup ^a   Kazzazi, Amir ^a   Momtahen, Shabnam ^b   Laze, Juliana ^a   Djavan, Bob ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

benign prostate hyperplasia; cytokines; immune response; inflammation; lower urinary tract symptoms; pathogenesis

Indexed keywords

ALLOANTIGEN; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; DOXAZOSIN; ELOCALCITOL; FINASTERIDE; GAMMA INTERFERON; GROWTH FACTOR; HERBACEOUS AGENT; IBUPROFEN; INTERLEUKIN 17; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ROFECOXIB;

ANGIOGENESIS; APOPTOSIS; CELL ACTIVITY; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHRONIC INFLAMMATION; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LOWER URINARY TRACT SYMPTOM; ORGAN SIZE; ORGAN WEIGHT; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TISSUE INJURY; TRANSURETHRAL RESECTION; TUMOR MICROENVIRONMENT; URINE RETENTION; WOUND HEALING;

AUTOIMMUNITY; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; OXIDATIVE STRESS; PROSTATIC HYPERPLASIA; PROSTATITIS;

EID: 84871264965     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835abd4a     Document Type: Review

References (55)

1. Djavan B, Margreiter M, Dianat SS. An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol 2011; 21:5-12.
2. Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev Urol 2005; 7 (Suppl. 9):S3-S14.
3. Juliao AA, Plata M, Kazzazi A, et al. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: Revisited. Curr Opin Urol 2012; 22:34-39.
4. Donnell RF. Benign prostate hyperplasia: A review of the year's progress from bench to clinic. Curr Opin Urol 2011; 21:22-26.
5. Emberton M, Fitzpatrick JM, Garcia-Losa M, et al. Progression of benign prostatic hyperplasia: Systematic review of the placebo arms of clinical trials. BJU Int 2008; 102:981-986.
6. Nickel JC, Roehrborn CG, O'Leary MP, et al. Examination of the relationship between symptoms of prostatitis and histological inflammation: Baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178 (3 Pt 1):896-900; discussion 900-901.
7. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008; 54:1379-1384.
8. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51:1202-1216. (Pubitemid 46436310)
9. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16:25-29. (Pubitemid 43041217)
10. Djavan B, Eckersberger E, Finkelstein J, et al. Benign prostatic hyperplasia: Current clinical practice. Prim Care 2010; 37:583-597; i.x.
11. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003; 43:164-175. (Pubitemid 36221971)
12. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol 1979; 121:755-760. (Pubitemid 9205780)
13. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172 (5 Pt 1):1784-1791. (Pubitemid 39363056)
14. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: Age-related tissue-remodeling. Exp Gerontol 2005; 40:121-128. (Pubitemid 40343002)
15. Djavan B, Eckersberger E, Espinosa G, et al. Complex mechanisms in prostatic inflammatory response. Eur Urol Suppl 2009; 8:872-878.
16. Steiner GE, Djavan B, Kramer G, et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 2002; 4:171-177.
17. Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33:475-488.
18. Roehrborn CG, Kaplan SA, NobleWD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. Results from the MTOPS study. J Urol 2005; 173(Suppl.):Abstract 1277.
19. Delongchamps NB, de la Roza G, Chandan V, et al. Evaluation of prostatitis in autopsied prostates - is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179:1736-1740.
20. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36:403-415; v.
21. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256-269. (Pubitemid 46486616)
22. Penna G, Fibbi B, Maggi M, Adorini L. Prostate autoimmunity: From experimental models to clinical counterparts. Expert Rev Clin Immunol 2009; 5:577-586.
23. Penna G, Fibbi B, Amuchastegui S, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009; 182:4056-4064.
24. Pace G, Di Massimo C, De Amicis D, et al. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol 2011; 37:617-622.
25. Roehrborn CG. Definition of at-risk patients: Baseline variables. BJU Int 2006; 97 (Suppl. 2):7-11; discussion 21-22.
26. Tuncel A, Uzun B, Eruyar T, et al. Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol 2005; 48:277-283; discussion 283-284.
27. Kefi A, Koseoglu H, Celebi I, et al. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol 2006; 40:155-160.
28. Mishra VC, Allen DJ, Nicolaou C, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100:327-331. (Pubitemid 47036563)
29. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2010; 171:571-582.
30. Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69:1774-1780.
31. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008; 35:109-115; vii
32. Briganti A, Capitanio U, Suardi N, et al. Benign prostatic hyperplasia and its aetiologies. Eur Urol Suppl 2009; 8:865-871.
33. Robert G, Descazeaud A, Allory Y, et al. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 2009; 8:879-886.
34. St Sauver JL, Jacobsen SJ. Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms. Curr Prostate Rep 2008; 6:67-73.
35. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52:43-58. (Pubitemid 34553191)
36. Wang L, Yang JR, Yang LY, Liu ZT. Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Med Hypotheses 2008; 70:1021-1023. (Pubitemid 351400693)
37. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol 2011; 60:106-117.
38. Yoo TK, Cho HJ. Benign prostatic hyperplasia: From bench to clinic. Korean J Urol 2012; 53:139-148.
39. Descazeaud A, Weinbreck N, Robert G, et al. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int 2011; 108 (2 Pt 2): E23-E28.
40. Starsichova A, Lincova E, Pernicova Z, et al. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. Cell Signal 2010; 22:1734-1744.
41. Bardia A, Platz EA, Yegnasubramanian S, et al. Anti-inflammatory drugs antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009; 9:419-426.
42. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10:580-593.
43. Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007; 103:689-693. (Pubitemid 46401347)
44. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005; 47:72-78; discussion 78-79.
45. Vela Navarrete R, Garcia Cardoso JV, Barat A, et al. BPH and inflammation: Pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44:549-555. (Pubitemid 37328630)
46. St Sauver JL, Jacobson DJ, McGree ME, et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164:760-768. (Pubitemid 44522080)
47. Sutcliffe S, Giovannucci E, De Marzo AM, et al. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am J Epidemiol 2005; 162:898-906. (Pubitemid 41541375)
48. Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62:27-33. (Pubitemid 39614290)
49. Sutcliffe S, Grubb Iii RL, Platz EA, et al. Nonsteroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2012; 110:1050-1059.
50. Kang D, Andriole GL, Van De Vooren RC, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int 2004; 93:1241-1245. (Pubitemid 38823945)
51. Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen. J Urol 2005; 174:375-379. (Pubitemid 40825761)
52. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004; 172 (5 Pt 1):1792-1799. (Pubitemid 39363057)
53. Habib FK. Serenoa repens: The scientific basis for the treatment of benign prostatic hyperplasia. Eur Urol Suppl 2009; 8:887-893.
54. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia). Prostate 2000; 45:259-266.
55. Lowe FC. The role of Serenoa repens in the clinical management of lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol Suppl 2009; 8:894-897.